How many therapeutic options are there for recurrent or metastatic salivary duct carcinoma?

Journal of Clinical Oncology

Volumn 30, Issue 6, 2012, Pages 672-

  Locati, Laura D ^a   Bossi, Paolo ^a   Licitra, Lisa ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; BEVACIZUMAB; TEMSIROLIMUS;

GENE OVEREXPRESSION; HUMAN; LETTER; METASTASIS; PRIORITY JOURNAL; RECURRENT CANCER; SALIVARY GLAND DISEASE; SALIVARY GLAND DUCT CARCINOMA;

HUMANS; MALE; PROTEIN KINASE INHIBITORS; SALIVARY DUCTS; SALIVARY GLAND NEOPLASMS; SIROLIMUS; SKIN NEOPLASMS;

EID: 84857620949     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.39.4577     Document Type: Letter

References (10)

1. Piha-Paul SA, Cohen PR, Kurzrock R: Salivary duct carcinoma: Targeting the phosphatidylinositol 3-kinase pathway by blocking mammalian target of rapamycin with temsirolimus. J Clin Oncol 29:e727-e730, 2011
2. Jaspers HC, Verbist BM, Schoffelen R, et al: Androgen receptor-positive salivary duct carcinoma: A disease entity with promising new treatment options. J Clin Oncol 29:e473-e476, 2011
3. Locati LD, Perrone F, Losa M, et al: Treatment relevant target immunophenotyping of 139 salivary gland carcinomas (SGCs). Oral Oncol 45:986-990, 2009
4. Barnes L, Eveson JW, Reichart P, et al: Tumours of the salivary glands, in Barnes L, Eveson JW, Reichart P et al (eds): WHO Classification of Tumours: Pathology and Genetics - Head and Neck Tumours. Lyon, France, IARC, 2005, pp 209-281
5. Locati LD, Mela M, Quattrone P, et al: Anti-androgen therapy in recurrent and/or metastatic salivary glands carcinoma (RSGC). Ann Oncol 14:126, 2003 (suppl 4)
6. Harris WP, Mostaghel EA, Nelson PS, et al: Androgen deprivation therapy: Progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol 6:76-85, 2009
7. Sircar K, Yoshimoto M, Monzon FA, et al: PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer. J Pathol 218:505-513, 2009
8. Carver BS, Chapinski C, Wongvipat J, et al: Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 19:575-586, 2011
9. Kaarbø M, Mikkelsen OL, Malerød L, et al: PI3K-AKT-mTOR pathway is dominant over androgen receptor signaling in prostate cancer cells. Cell Oncol 32:11-27, 2010
10. Kelly WK, Halabi S, Carducci MA, et al: A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): Survival results of CALGB 90401. J Clin Oncol 28:951s, 2010 (suppl 15; abstr LBA4511)